CAR T cells require optimization to be effective in patients with solid tumors. There are many barriers affecting their ability to succeed. One barrier is persistence, as to achieve an optimal antitumor response, infused CAR T cells must engraft and persist. This singular variable is impacted by a multitude of factors—the CAR T cell design, lymphodepletion regimen used, expansion method to generate the T cell product, and more. Additionally, external agents can be utilized to augment CAR T cells, such as the addition of novel cytokines, pharmaceutical drugs that bolster memory formation, or other agents during either the ex vivo expansion process or after CAR T cell infusion to support them in the oppressive tumor microenvironment. This review highlights many strategies being used to optimize T cell persistence as well as future directions for improving the persistence of infused cells.
CAR T细胞在实体瘤患者中的疗效仍需优化，其应用面临多重障碍。其中关键障碍在于细胞持久性——为实现最佳抗肿瘤反应，回输的CAR T细胞必须成功定植并长期存活。这一核心变量受多种因素影响，包括CAR T细胞设计、淋巴细胞清除方案、T细胞产品的扩增方法等。此外，可通过外部干预手段增强CAR T细胞功能，例如在体外扩增过程中或细胞回输后，联合使用新型细胞因子、促进记忆形成的药物或其他制剂，以帮助细胞在抑制性肿瘤微环境中维持活性。本综述系统阐述了当前优化T细胞持久性的多种策略，并对提升回输细胞持续存活能力的发展方向进行展望。
Strategies for Improving CAR T Cell Persistence in Solid Tumors
肿瘤(癌症)患者之家